reviewTop 1% cited

Epidermal growth factor receptor mutations in lung cancer

Nature reviews. Cancer · 2007 · Vol. 7(3) · pp. 169–181

Sreenath V. Sharma✉Daphne W. Bell(Harvard University)Jeffrey Settleman(Massachusetts General Hospital)Daniel A. Haber(Harvard University)

View via DOI Publisher page

Lung Cancer Treatments and Mutations PI3K/AKT/mTOR signaling in cancer HER2/EGFR in Cancer ResearchEpidermal growth factor receptorLung cancerSomatic cellCancer researchBiologyTargeted therapyCancerMedicineGeneOncology

MeSH terms

AnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMutationDrug Resistance, NeoplasmProtein Kinase InhibitorsErbB Receptors

Funding

National Institutes of Health

Citations

3,115

FWCI

97.22

field-weighted impact

References

182

Percentile

100%

vs. same field & year

Citations per year

Cited by

Cancer Genome Landscapes

Science · 2013 · 7,937 citations

The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Oncotarget · 2016 · 768 citations

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Journal of Clinical Oncology · 2013 · 3,181 citations

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The Lancet Oncology · 2015 · 1,573 citations

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Oncogene · 2009 · 979 citations

Cell death-based treatment of lung adenocarcinoma

Cell Death and Disease · 2018 · 781 citations

Cell Signaling by Receptor Tyrosine Kinases

Cell · 2010 · 7,809 citations

Targeting the RAF–MEK–ERK pathway in cancer therapy

Cancer Letters · 2009 · 483 citations

References

ERBB receptors and cancer: the complexity of targeted inhibitors

Nature reviews. Cancer · 2005 · 3,292 citations

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

International Journal of Cancer · 2005 · 661 citations

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

JNCI Journal of the National Cancer Institute · 2005 · 1,568 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

PLoS Medicine · 2005 · 3,519 citations

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Nature Medicine · 1996 · 3,643 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

New England Journal of Medicine · 2004 · 11,455 citations

EGFR and cancer prognosis

European Journal of Cancer · 2001 · 2,135 citations

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Bioorganic & Medicinal Chemistry Letters · 2001 · 559 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.